Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing EGFR Alterations

BACKGROUND: EGFR alterations are commonly observed in malignant gliomas (MG). Osimertinib, an irreversible EGFR-tyrosine kinase inhibitor, effectively penetrates the blood brain barrier and achieves therapeutic concentrations in brain tissue. MATERIALS AND METHODS: This retrospective chart review id...

Descripción completa

Detalles Bibliográficos
Autores principales: Abousaud, Marin, Faroqui, Naqeeb M, Lesser, Glenn, Strowd, Roy E, Ramkissoon, Shakti H, Kwatra, Madan, Houston, Kristin S, Hsu, Fang-Chi, Carter, Annette, Petro, Robin, DeTroye, Alisha T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121798/
https://www.ncbi.nlm.nih.gov/pubmed/35601813
http://dx.doi.org/10.26502/jcsct.5079114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121798/
https://www.ncbi.nlm.nih.gov/pubmed/35601813
http://dx.doi.org/10.26502/jcsct.5079114

Ejemplares similares